Autologous Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics

Drug Profile

Autologous Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics

Alternative Names: ATA 190; Autologous ATA188; Autologous ATA190; Autologous Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics; EBV-CTL - Atara Biotherapeutics

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Atara Biotherapeutics; Memorial Sloan-Kettering Cancer Center
  • Developer QIMR Berghofer Medical Research Institute
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 01 Aug 2018 Atara Biotherapeutics plans a randomised autologous ATA 190 trial in progressive Multiple sclerosis in 2019
  • 01 Jun 2018 Atara Biotherapeutics exercises its option with QIMR Berghofer to an exclusive, worldwide license to develop and commercialise additional T-cell immunotherapy programmes, including ATA 190, and additional technology
  • 25 Oct 2017 Updated efficacy and adverse events data from a phase I trial in Multiple sclerosis released by Atara Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top